Stay updated on Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial
Sign up to get notified when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.

Latest updates to the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page
- Check3 days agoChange DetectedSite revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange Detected- Version history updated: Revision v3.5.0 added; Revision v3.4.3 removed.SummaryDifference0.1%

- Check46 days agoChange DetectedVersion bump from v3.4.2 to v3.4.3; study details and user-facing content remain the same.SummaryDifference0.1%

- Check67 days agoChange DetectedAdded 'Gastric cancer' as a keyword and included the Genetic and Rare Diseases Information Center under Resources. Page revision updated from v3.4.1 to v3.4.2.SummaryDifference0.2%

- Check74 days agoChange DetectedA minor page revision tag was added: Revision: v3.4.1, updating from v3.4.0, with no changes to study content or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check96 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4. No substantive changes to the study details page are evident.SummaryDifference0.1%

Stay in the know with updates to Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.